News Minimalist logo

JYNNEOS® is now available as the only FDA-approved mpox vaccine in the U.S

GlobeNewswire — April 2, 2024, 07:00 AM UTC

Summary: Bavarian Nordic A/S announced the commercial availability of JYNNEOS®, the only FDA-approved mpox vaccine in the U.S. Since 2022, over 32,000 mpox cases have been reported in the U.S. with 60% of eligible individuals unvaccinated. JYNNEOS is now recommended for routine use in at-risk individuals 18 years and older. The vaccine is available nationwide through healthcare providers, aiming to increase awareness and availability.

Full article

Article metrics

The article metrics are deprecated.

I'm replacing the original 8-factor scoring system with a new and improved one. It doesn't use the original factors and gives much better significance scores.

Timeline:

  1. [4.9]
    Jynneos vaccine crucial for preventing monkeypox spread (Pharmaceutical Technology)
    114d
    Source
  2. [6.0]
    Bavarian Nordic launches Jynneos monkeypox vaccine in US (Pharmaceutical Technology)
    115d

    ScoresSource
  3. [5.4]
    Mpox cases rise in 2024, JYNNEOS vaccine recommended (Livescience.com)
    116d

    ScoresSource
  4. [4.7]
    Monkeypox cases rising in the US, emphasize vaccination coverage (TheHealthSite)
    119d
    Source
  5. [4.7]
    Ontario sees spike in mpox cases, urges vaccination (CP24)
    120d
    Source
  6. [5.8]
    US mpox cases double from last year, vaccination crucial (CNN)
    121d

    ScoresSource